Auriga Comments On Cerner Q1 Preview

According to Auriga, Cerner (NASDAQ: CERN) is well positioned across the board for 2011.

Auriga said that it continues to recommend purchase of Cerner (CERN) following our upgrade last month as the single best way to play the health IT stimulus, domestically and abroad. “Our checks suggest that Cerner is demonstrating success in the acute care replacement market as hospitals scramble to meet requirements for meaningful use, and its ambulatory solutions (while not the Company's strength) are gaining ground. Longer term, we view Cerner as way out in front of any hospital IT vendor vis-a-vis its global footprint and for this reason believe the stock is a core holding even when our current stimulus “runs out” (which is still 3-4 years away).”

Cerner closed yesterday at $111.43.